Production (Stage)
Arcutis Biotherapeutics, Inc.
ARQT
$13.98
$0.322.34%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -132.30% | 74.03% | 20.63% | -47.91% | 46.62% |
| Total Depreciation and Amortization | 583.84% | -68.02% | 307.98% | -1.96% | -7.01% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -17.17% | 20.91% | -17.14% | 25.57% | -4.12% |
| Change in Net Operating Assets | -1,028.72% | 58.81% | 10.85% | 21.59% | -1,424.09% |
| Cash from Operations | -3,961.50% | 97.84% | 23.12% | -42.77% | 43.81% |
| Capital Expenditure | -- | 100.00% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -64.57% | -58.93% | 236.67% | -116.53% | 53.85% |
| Cash from Investing | -66.31% | -58.86% | 236.44% | -116.53% | 53.85% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -84.74% | 557.11% | -72.92% | -99.10% | 62.92% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 100.41% | -24,823.60% | -72.92% | -99.10% | 62.92% |
| Foreign Exchange rate Adjustments | 101.71% | -338.78% | 476.92% | 64.38% | -207.35% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 71.30% | -225.57% | 147.80% | -204.38% | 631.59% |